— Know what they know.
Not Investment Advice

NRIX NASDAQ

Nurix Therapeutics, Inc.
1W: +9.6% 1M: +5.4% 3M: +11.1% YTD: -2.9% 1Y: +72.9% 3Y: +78.3% 5Y: -32.5%
$17.50
-0.03 (-0.17%)
 
Weekly Expected Move ±4.3%
$14 $15 $16 $17 $17
NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 58 · $1.5B mcap · 87M float · 1.27% daily turnover · Short 65% of daily vol

Balance Sheet Trends

Total Assets
$688M +2.8% ▲
5Y CAGR: +11.7%
Total Liabilities
$149M +4.9% ▲
5Y CAGR: +7.1%
Shareholders Equity
$539M +2.2% ▲
5Y CAGR: +13.2%
Cash & Investments
$593M -2.7% ▼
5Y CAGR: +16.1%
Total Debt
$56M +96.9% ▲
Net Debt
-$191M -134.1% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$81M$64M$55M$110M$247M
Short-Term Investments$215M$245M$233M$500M$346M
Cash & ST Investments$296M$309M$288M$610M$593M
Net Receivables$6M$1M$800K$2M$0
Inventory$0-$1M$0$0$0
Other Current Assets$900K$9M$7M$8M$14M
Total Current Assets$311M$318M$296M$619M$607M
Property, Plant & Equip.$25M$30M$48M$46M$73M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$137M$64M$7M$0$0
Other Non-Current Assets$3M$5M$5M$4M$8M
Total Non-Current Assets$166M$98M$60M$50M$81M
Total Assets$477M$417M$356M$669M$688M
— Liabilities —
Accounts Payable$7M$5M$6M$11M$11M
Short-Term Debt$4M$6M$7M$0$0
Deferred Revenue$41M$38M$48M$38M$18M
Other Current Liabilities$6M$9M$751K$19M$24M
Total Current Liabilities$66M$71M$87M$96M$86M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$68M$42M$68M$46M$63M
Total Liabilities$134M$113M$155M$142M$149M
— Equity —
Common Stock$45K$47K$49K$76K$102K
Retained Earnings-$221M-$401M-$545M-$739M-$1.0B
Accumulated OCI-$608K-$4M-$655K$150K$105K
Total Stockholders Equity$342M$304M$200M$527M$539M
Total Liabilities & Equity$477M$417M$356M$669M$688M
— Key Metrics —
Total Debt$13M$12M$31M$28M$56M
Net Debt-$67M-$53M-$24M-$82M-$191M
Total Investments$352M$309M$241M$500M$346M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms